ABTI (Alterola Biotech) Notes Receivable: $0.00 Mil (As of Sep. 2024)


What is Alterola Biotech Notes Receivable?

Alterola Biotech ABTI Notes Receivable is $0.00 Mil as of Sep. 2024.

Alterola Biotech's Notes Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


Alterola Biotech Notes Receivable Related Terms


Alterola Biotech Notes Receivable Historical Data

* Premium members only.

The historical data trend for Alterola Biotech's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterola Biotech Notes Receivable Chart

Alterola Biotech Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Mar22 Mar23 Mar24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterola Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterola Biotech Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Alterola Biotech (ABTI) has a Notes Receivable of $0.00 Mil as of Sep. 2024. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Alterola Biotech and its competitors.
Is Alterola Biotech's Notes Receivable too high?
Alterola Biotech's current Notes Receivable is $0.00 Mil.
How does Alterola Biotech's Notes Receivable compare to SKYI and GCAN?
Alterola Biotech's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Alterola Biotech and its competitors. Alterola Biotech's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterola Biotech stock overvalued right now?
Alterola Biotech (ABTI) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Alterola Biotech (ABTI), the current Notes Receivable is $0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterola Biotech Business Description

Address 47 Hamilton Square, Birkenhead, Merseyside, GBR, CH41 5AR
Alterola Biotech Inc is a pharmaceutical company working with cannabinoid and cannabinoid-like molecules. The company operates in three focus areas: Development of regulated pharmaceuticals (human and animal health) and regulated food products; Production of low cost of goods Active Pharmaceutical Ingredient (API) and food-grade ingredients; and Formulation, and drug delivery, providing improved bioavailability, solubility and stability.